Dr. Marc D. Benevides, MD

Dr. Benevides practices at The Bryn Mawr Urology Group in Rosemont, Pennsylvania.

Dr. Benevides' NPI, 1194765784, was assigned on June 8, 2006. Dr. Benevides graduated from University of North Carolina School of Medicine in 1995. Dr. Benevides holds North Carolina license 200100014.

Dr. Benevides' primary practice is The Bryn Mawr Urology Group, at 919 Conestoga Road, Rosemont, PA 19010. The practice phone is (610) 525-6580. Dr. Benevides also practices at Academic Urology of PA, LLC, 2 Industrial Blvd, Paoli, PA 19301.

Dr. Benevides' primary practice is The Bryn Mawr Urology Group in Rosemont, Pennsylvania. Dr. Benevides is also affiliated with Duke University Hospital. The medical group on file is MidLantic Urology. Dmand AI also links Dr. Benevides to 2 more hospitals, 2 group practices and clinics, 1 physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Benevides practices, 7 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Benevides' primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Benevides is board certified in urology by the American Board of Urology. Dr. Benevides is licensed in North Carolina.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney disease, kidney stone disease, kidney stones and prostate cancer among the conditions Dr. Benevides treats.

CMS data shows 6,604 Medicare services from Dr. Benevides across 27 procedure codes in 2024, for 994 Medicare patients. Medicare paid $161,970 for them.

CMS counts 994 Medicare patients who saw Dr. Benevides in 2024. The largest group is 65 to 74, with 484 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 2% are also on Medicaid. Their average risk score is 0.94, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Benevides' median patient age at 68, with 10% women.

In 2024, Dr. Benevides wrote 3,905 Medicare Part D claims for 989 patients. 86% of them were for generic drugs. CMS names the drug for 3,725 of them, across 26 drugs with 11 or more claims each, at $588,071 in total drug cost. In 2023, CMS named 3,430 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Benevides for performance year 2024, reported as part of a group. Dr. Benevides accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Benevides. The most frequent topics are Vasodilator Agents. Dr. Benevides has published most often in J Urol.

CMS Open Payments shows 628 general payments to Dr. Benevides from 53 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Astellas Pharma US Inc paid the most, $2,703.

Dmand AI lists 2 awards for Dr. Benevides, most recently CMS Stage 1 2012 in 2012.

Dr. Benevides graduated from University of North Carolina School of Medicine in 1995.

Dr. Benevides is in network with 18 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.